Arrowhead Pharmaceuticals (ARWR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$57.46-6.80%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ARWR
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | Sep 2014 | Sep 2013 | Sep 2012 | Sep 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 669.5 | 829.4 | 3.6 | 240.7 | 243.2 | 138.3 | 88.0 | 168.8 | 16.1 | 31.4 | 0.2 | 0.4 | 0.2 | 0.3 | 0.1 | 0.3 |
| Total Revenues | — | — | — | — | — | — | — | — | 16.1 | 31.4 | 0.2 | 0.4 | 0.2 | 0.3 | 0.1 | 0.3 |
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | 723.4 | 607.2 | — | 353.2 | — | — | — | — | — | — | — | 47.3 | 23.1 | 8.7 | 5.4 | 3.3 |
| Operating Income | (226.4) | 98.3 | (601.1) | (205.0) | (178.5) | (149.0) | (93.2) | 61.2 | (55.9) | (37.0) | (81.7) | (96.0) | (53.3) | (24.6) | (21.1) | (9.8) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 89.4 | 32.4 | 18.3 | 0.0 | 0.0 | — | — | — | — | — | — | — | — | — | — |
| Other Non-Operating Income / Expenses | (25.6) | (46.8) | (11.4) | (1.5) | 5.8 | 8.2 | 8.6 | 7.0 | 1.5 | 2.6 | 0.0 | 4.0 | (5.4) | (7.1) | (1.0) | 1.0 |
| Asset Writedown | — | — | — | — | — | — | — | — | 2.1 | 2.1 | 2.1 | — | — | — | — | — |
| EBT, Incl. Unusual Items | (252.1) | 51.5 | (612.5) | (206.5) | (172.7) | (140.8) | (84.6) | 68.1 | (54.4) | (34.4) | (81.7) | (91.9) | (58.7) | (31.7) | (22.1) | (8.8) |
| Income Tax Expense | 20.0 | 21.4 | (2.8) | 2.8 | 3.8 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — |
| Earnings from Continuing Operations | — | — | — | — | — | — | — | — | — | — | — | (91.9) | (58.7) | (31.7) | (22.1) | (8.8) |
| Net Income | ||||||||||||||||
| Minority Interest | 47.8 | 31.7 | (10.2) | (4.0) | (0.4) | 0.0 | 0.0 | — | — | — | (0.1) | (0.1) | (0.1) | (0.6) | (1.0) | (0.4) |
| Net Income | (320.0) | (1.6) | (599.5) | (205.3) | (176.1) | (140.8) | (84.6) | 68.0 | (54.5) | (34.4) | (81.7) | (91.9) | (58.6) | (31.1) | (21.1) | (3.1) |
| Per Share | ||||||||||||||||
| Basic EPS | (2.23) | (0.01) | (5.00) | (1.92) | (1.67) | (1.36) | (0.84) | 0.72 | — | — | — | — | — | — | (1.90) | (0.44) |
| Diluted EPS | (2.23) | (0.01) | (5.00) | (1.92) | (1.67) | (1.36) | (0.84) | 0.69 | — | — | — | — | — | — | — | (0.40) |
| Revenue per Share | 4.67 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 143.4 | 133.8 | 119.8 | 106.8 | 105.4 | 103.7 | 100.7 | 93.9 | — | — | — | — | — | — | 11.1 | 7.2 |
| Diluted Weighted Avg Shares | 143.4 | 133.8 | 119.8 | 106.8 | 105.4 | 103.7 | 100.7 | 98.6 | — | — | — | — | — | — | — | 7.8 |
| Supplemental | ||||||||||||||||
| EBITDA | — | 122.3 | (582.5) | (192.5) | (168.1) | (140.8) | (87.2) | 65.6 | (51.2) | (32.3) | (78.5) | (93.6) | (51.9) | (22.8) | (19.3) | (9.6) |
| EBIT | (226.4) | 98.3 | (601.1) | (205.0) | (178.5) | (149.0) | (93.2) | 61.2 | (55.9) | (37.0) | (81.7) | (96.0) | (53.3) | (24.6) | (21.1) | (9.8) |
| Effective Tax Rate | -8.0% | — | — | -1.3% | -2.2% | -0.0% | -0.0% | 0.3% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.